-?53.0 million in cash and cash equivalents as of June 30, 2015
-Full year 2015 cash burn guidance reduced to ?35-40 million
Strasbourg, France, September 10, 2015 – Transgene SA (Euronext: TNG) today announced its financial results for the six-month period ended June 30, 2015.
Revenue for the six-month period ended June 30, 2015 amounted to ?5.3 million, compared to ?6.1 million for the same period in 2014. Government financing for research expenditures accounted for the majority of revenue, with ?4.5 million for the first six months of 2015 compared to ?5.0 million for the same period in 2014.
Research and development expenses amounted to ?16.9 million for the first six months of 2015, compared to ?21.8 million for the first six months of 2014, at constant perimeter . This decrease was mainly due to the completion of the phase 2b clinical trials of TG4010 and Pexa-Vec.
General and administrative expenses amounted to ?2.9 million for the first six months of 2015, compared to ?3.8 million for the same period in 2014. This decrease was mainly due to a staff decrease in financial and administrative support functions, a consequence of a reallocation of internal resources.
1 commentaire
Vous devez être membre pour ajouter un commentaire.
Vous êtes déjà membre ? Connectez-vous
Pas encore membre ? Devenez membre gratuitement
Signaler le commentaire
Fermer